Hematological effects of intermittent 2-hour infusions of cladribine in multiple sclerosis patients: A comparison of 2 dosage patterns

International Journal of Hematology

Volumn 74, Issue 4, 2001, Pages 421-427

  Grieb, Paweł ^a   Kamienowski, Jerzy ^b   Janisz, Monika ^a   Kuśnierczyk, Piotr ^c   Kawiak, Jerzy ^d   Hoser, Grazyna ^d   Chrapusta, Stanislaw J ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^b T Marciniak Lower Silesia Specialist Hospital Wroclaw   (Poland)

^c INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^d MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Cladribine; Erythrocytes; Leukocytes; Lymphocytes; Multiple sclerosis

Indexed keywords

CLADRIBINE;

ADULT; ARTICLE; BLOOD; BLOOD CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HUMAN; LYMPHOCYTE SUBPOPULATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

ADULT; BLOOD CELL COUNT; CLADRIBINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 0035751468     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982086     Document Type: Article

References (25)

1. Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet. 1997;32:120-131.
2. Carson DA, Wasson DR, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983;62:737-743.
3. Cheson BD, Sorensen JM, Vena DA, et al.Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol. 1998;16:3007-3015.
4. Dearden CE, Matutes E, Hilditch BL, Swansbury GJ, Catovsky D. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br J Haematol. 1999;106: 515-519.
5. Rummel MJ, Chow KU, Jager E, et al. Intermittent 2-hour infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. Leuk Lymph. 1999;35:129-138.
6. Fridrik MA, Jager G, Baldinger C, Krieger O, Chott A, Bettelheim P. First-line treatment of Waldenström's disease with cladribine. Ann Hematol. 1997;74:7-10.
7. Robak T, Błoński JZ, Kasznicki M, et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia-updated results of the multicentre study of 378 patients. Br J Haematol. 2000;108: 357-368.
8. Eibschutz B, Baird SM, Weisman MH, et al. Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary report. Arthritis Rheum. 1995;38:1604-1609.
9. Schirmer M, Mur M, Pfeiffer KP, Thaler J, Konwalinka G. The safety profile of low-dose cladribine in refractory rheumatoid arthritis: a pilot trial. Scand J Rheumatol. 1997;26:376-379.
10. Langtry HD, Lamb HM. Cladribine: a review of its use in multiple sclerosis. BioDrugs. 1998;9:419-433.
11. Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians. 1999;111: 35-44.
12. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet. 1992;340: 952-956.
13. Arner ES, Spasokoukotskaja T, Juliusson G, Liliemark J, Eriksson S. Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic patients. Br J Haematol. 1994;87:715-718.
14. Chow KU, Rummel MJ, Weidmann E, et al. Induction of apoptosis by 2-chloro-2′-deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: Synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone. Leuk Lymph. 2000;36:559-567.
15. Robak T, Błasińska-Morawiec M, Krykowski E, et al. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymph. 1996;22:107-111.
16. van den Neste E, Delannoy A, Vandercam B, et al. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol. 1996;56:235-240.
17. Chacko J, Murphy C, Duggan C, O'Briain DS, Browne PV, McCann SR. Weekly intermittent 2-CdA is less toxic and equally efficacious when compared to continuous infusion in hairy cell leukaemia. Br J Haematol. 1999;105:1145-1146. :
18. Lauria F, Bocchia M, Marotta G, Raspadori D, Zinzani PL, Rondelli D. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica. 1999;84:22-25.
19. Beutler E, Koziol JA, McMillan R, Sipe JC, Romine JS, Carrera CJ. Marrow suppression produced by repeated doses of cladribine. Acta Haematol. 1994;91:10-15.
20. Grieb P, Ryba M, Stelmasiak Z, Nowicki J, Solski J, Jakubowska B. Cladribine treatment of multiple sclerosis. Lancet. 1994;344: 537-538.
21. Carrera CJ, Terai C, Lotz M, et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. J Clin Invest. 1990;86:1480-1488.
22. Bilgeri R, Petzer AL, Zilian U, et al. Effect of deoxycytidine on 2-chloro-deoxyadenosine-mediated growth inhibition of normal human erythroid and myeloid progenitor cells. Exp Hematol. 1993; 21:432-437.
23. Rice GPA, Filippi M, Comi G. Cladribine and progressive MS - clinical and MRI outcomes of a multicenter controlled trial. Neurology. 2000;54:1145-1155.
24. Selby R, Brandwein J, O'Connor P. Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis. Can J Neural Sci. 1998;25:295-299.
25. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol. 1995;13:2431-2448.